Status:
COMPLETED
Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance
Lead Sponsor:
Glostrup University Hospital, Copenhagen
Collaborating Sponsors:
Bispebjerg Hospital
University Hospital, Gentofte, Copenhagen
Conditions:
Migraine Without Aura
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
The purpose of this study is to examine and compare the effect of pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on intracranial arteries a...
Eligibility Criteria
Inclusion
- Healthy migraine patient without aura
- Age 18-40
- Weight 50-100 kg
- Fertile women must use safe contraceptives
Exclusion
- Tension type headache more than 5 days per month
- Other primary headaches
- Daily use of medication except contraceptives
- Drug taken within 4 times the half life for the specific drug except contraceptives
- Pregnant or lactating women
- Exposure to radiation within the last year
- Hypotension or hypertension
- Cardiovascular or cerebrovascular disease
- Mental illness or substance abuse
- Other significant conditions determined by the examining doctor
- Contraindications to MRI scan
- Headache within the last 48 hours before start of trial
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01471990
Start Date
May 1 2011
End Date
June 1 2012
Last Update
August 29 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen
Glostrup Municipality, Denmark, DK-2600